12:00 AM
 | 
Sep 20, 1999
 |  BC Week In Review  |  Company News  |  Deals

Oxford GlycoSciences, Pfizer deal

Under a 1998 agreement, Pfizer exercised its option to use OGS's proteomics technology to identify disease-specific proteins for a second...

Read the full 77 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >